Premium
Retinoid differentiation therapy in promyelocytic leukemia
Author(s) -
Chomienne Christine,
Fenaux Pierre,
Degos Laurent
Publication year - 1996
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.10.9.8801163
Subject(s) - acute promyelocytic leukemia , retinoic acid , retinoid , myeloid leukemia , leukemia , promyelocytic leukemia protein , cancer research , differentiation therapy , medicine , fusion gene , biology , immunology , gene , genetics
Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia characterized by the morphology of the blast cells, a specific t(15;I7) translocation, and risks of definite coagulopathy. Recently this leukemia was further characterized by an exquisite sensitivity to all‐trans retinoic acid's differentiation effect and the production of a fusion gene altering the gene of RARα and a novel gene PML. In vivo differentiation therapy with retinoids in APL patients follows strict guidelines related both to the APL cell and the biodisposal of all‐Iran retinoic acid.—Chomienne, C., Fenaux, P., Degos, L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J. 10,1025‐1030 (1996)